This narrative review looks at how multi-omic technologies and computational biology might change care for pediatric patients with sepsis. The study was not a clinical trial but a review of existing information. It compared these advanced methods against single marker approaches used today.
The main finding is that these new tools could help with biomarker discovery and clinical translation. The authors believe this could transform care by moving away from empiric treatment toward precision medicine. No specific safety concerns were reported because this was a review, not a test of a new drug or device.
Readers should understand that this is a narrative review, not a large clinical trial. The sample size was not reported, and the study phase was not specified. While the potential is significant, the evidence is limited to what has been published so far. This information helps explain the direction of future research but does not yet change current practice guidelines.
